The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.60
Bid: 13.50
Ask: 13.70
Change: 0.00 (0.00%)
Spread: 0.20 (1.481%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 13.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Metal Tiger goes into the Strata but out of AIM

Thu, 02nd Mar 2023 11:14

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Verici Dx PLC, up 21% at 9.1 pence, 12-month range 11p-40p. The Tennessee-based developer of clinical diagnostics for organ transplants says it achieves CLIA compliance certification for its commercial clinical operations to 45 US states. Now intends to ramp up commercialisation of its advanced kidney transplant service offering, which includes Tutivia. "This milestone of certification is also a key requirement to obtaining insurance reimbursement coverage under Medicare under the local coverage determination application being submitted this year," Verici explains.

----------

Poolbeg Pharma PLC, up 22% at 10.35p, 12-month range 4p-11.1p. The infectious disease-focused biopharmaceutical company announces positive data from the POLB 001 LPS human challenge trial. POLB 001 is a bacterial lipopolysaccharide treatment being developed for severe influenza. Poolbeg says the treatment was shown to be safe, well tolerated and potent against systemic and localised inflammation. The results show POLB 001's potential as a "blockbuster treatment" for severe influenza, the firm says.

----------

AIM - LOSERS

----------

Totally PLC, down 26% at 21p, 12-month range 20p-49.19p. The healthcare provider says it expects earnings before interest, tax, depreciation and amortisation to be around GBP6.3 million, which is below market consensus, for the financial year ending March 31. "The company has...been impacted by the combined impact of high inflation, national strikes, which increase pressure on services and scheduling, and clinical workforce shortages which increase reliance on agency staff for the delivery of urgent care services," Totally explains. Expects revenue to be in line with market consensus, and remains confident in its prospects.

----------

Metal Tiger, down 25% at 9.37p, 12-month range 8.55p-22.45p. The investor in natural resource opportunities plans to delist from AIM, in order to pursue a more "active" strategy than the listing requirements currently permit. Has abandoned previous notion of listing on the Specialist Fund Segment of London's Main Market. Will retain listing on Australian Securities Exchange. "The board believes that this will result in the company having greater flexibility to manage its portfolio," it explains. Will hold general meeting on March 20 for shareholder vote. Also, plans to change name to Strata Investment Holdings PLC, but notes this does not require shareholder approval.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 May 2024 16:39

Poolbeg Pharma celebrates full patent approval for Immunomodulator II

(Alliance News) - Poolbeg Pharma PLC on Wednesday said that it has received a fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Read more
30 Apr 2024 16:43

Poolbeg agrees 12-month option over potential Behcet's treatment

(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).

Read more
30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Mar 2024 11:10

Poolbeg Pharma to be granted US patent

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

Read more
19 Feb 2024 14:22

Director dealings: Poolbeg Pharma co-founder ups stake

(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.

Read more
15 Feb 2024 16:02

TRADING UPDATES: Diversified Energy offers dividend alternative

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Feb 2024 19:44

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
12 Feb 2024 14:37

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.

Read more
17 Jan 2024 13:58

Poolbeg Pharma hails POLB 001'S potential to treat CRS

(Alliance News) - Poolbeg Pharma PLC on Wednesday noted "promising" results for POLB 001's potential in treating cancer immunotherapy-induced cytokine release syndrome.

Read more
20 Dec 2023 20:00

TRADING UPDATES: K3 Business says cash balances ahead of forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Dec 2023 13:54

Poolbeg makes promising progress with RSV programme

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

Read more
21 Nov 2023 14:39

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
9 Nov 2023 16:57

IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

Read more
17 Oct 2023 10:49

Poolbeg Pharma shares up on metabolic drug collaboration agreement

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has agreed to collaborate with an unnamed Nasdaq-listed biopharmaceutical company for the development of an optimised oral drug to treat a metabolic condition.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.